The Michael J. Fox Foundation for Parkinson's Research has announced seventeen grants totaling more than $3 million to researchers working to accelerate PD therapeutic development.
The grants, which complement those of MJFF's annual Pipeline Programs and Critical Challenges in Parkinson's Disease initiatives, were awarded to John Sinclair of the University of Cambridge, who will continue his investigation into the possible use of viral RNA to protect the neurons that die in PD; Gregory A. Petsko of Brandeis University, who will investigate shapes that the protein alpha-synuclein may take within cells that can lead to its aggregation into Lewy bodies, a pathological hallmark of PD; and Jochen Weishaupt of the University Hospital Göttingen in Germany, who will test an enhanced form of the growth factor G-CSF in relevant pre-clinical models.
Additional grantees include Daniela Berg of the University of Tübingen in Germany; Ivan Bodis-Wollner of SUNY Downstate Medical Center; Gully Burns of the University of Southern California; Angela Cenci-Nilsson of Lund University; John W. Commissiong of Amarantus Therapeutics; Karl Kieburtz of the University of Rochester Medical Center; Jeffrey H. Kodower and T. Celeste Napier of Rush University Medical Center; Joshua Salafsky of Biodesy LLC; Eric V. Shusta of the University of Wisconsin, Madison; David G. Standaerdt of the University of Alabama at Birmingham; Raymond Swanson of the University of California, San Francisco; Michael W. Weiner of the Northern California Institute for Research and Education; and Xiangdong Yang of the University of California, Los Angeles.
For information on each of the research projects, visit the MJFF Web site.